Aktienanalyse wird geladen …
TMO · NYSE · Diagnostics & Research · USA
678,63 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 44,56 Mrd. | 6,7 Mrd. | 17,74 $ | 378 Mio. | 0,5 Mio · 0,1 % | 5,5 Mio · 1,4 % | 40,9 % | 15,1 % | 16,65 $ | 0,82 $ | 1,72 $ |
| 2024 | 42,88 Mrd. | 6,34 Mrd. | 16,53 $ | 383 Mio. | 0,4 Mio · 0,1 % | 5,4 Mio · 1,4 % | 41,3 % | 14,8 % | 18,97 $ | 0,79 $ | 1,56 $ |
| 2023 | 42,86 Mrd. | 6 Mrd. | 15,45 $ | 388 Mio. | 0,4 Mio · 0,1 % | 6,4 Mio · 1,7 % | 39,9 % | 14 % | 17,85 $ | 0,72 $ | 1,40 $ |
| 2022 | 44,92 Mrd. | 6,95 Mrd. | 17,63 $ | 394 Mio. | 0,5 Mio · 0,1 % | 3,5 Mio · 0,9 % | 42,2 % | 15,5 % | 17,54 $ | 0,78 $ | 1,20 $ |
| 2021 | 39,21 Mrd. | 7,73 Mrd. | 19,46 $ | 397 Mio. | 0,3 Mio · 0,1 % | 2,3 Mio · 0,6 % | 50,1 % | 19,7 % | 17,10 $ | 0,58 $ | 1,04 $ |
| 2020 | 32,22 Mrd. | 6,38 Mrd. | 15,96 $ | 399 Mio. | 0,3 Mio · 0,1 % | 4,3 Mio · 1,1 % | 49,7 % | 19,8 % | 17,08 $ | 0,49 $ | 0,88 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q2 2026 | 11,99 Mrd. | 1,74 Mrd. | 4,68 $ | 371 Mio. | 14,5 % | 4,51 $ |
| Q1 2026 | 11,01 Mrd. | 1,65 Mrd. | 4,43 $ | 373 Mio. | 15 % | 2,19 $ |
| Q4 2025 | 12,22 Mrd. | 1,96 Mrd. | 5,20 $ | 377 Mio. | 16,1 % | 7,92 $ |
| Q3 2025 | 11,12 Mrd. | 1,62 Mrd. | 4,28 $ | 378 Mio. | 14,5 % | 4,85 $ |
| Q2 2025 | 10,86 Mrd. | 1,62 Mrd. | 4,28 $ | 378 Mio. | 14,9 % | 2,92 $ |
| Q1 2025 | 10,36 Mrd. | 1,51 Mrd. | 3,98 $ | 379 Mio. | 14,5 % | 0,95 $ |
| Q4 2024 | 11,4 Mrd. | 1,83 Mrd. | 4,84 $ | — | 16,1 % | 7,43 $ |
| Q3 2024 | 10,6 Mrd. | 1,63 Mrd. | 4,24 $ | 384 Mio. | 15,4 % | 4,93 $ |
Dodge and Cox’s Bullish Stance on Thermo Fisher Scientific (TMO)
Cell Isolation/Cell Separation Market Forecasts Growth from $6.97B (2026) to $13.51B by 2032, Profiling Thermo Fisher, Bio-Rad, Beckman Coulter & Sartorius
TDM Reagent Kit Market Forecasts Growth from $2.87B (2026) to $6.96B by 2032, Profiling Abbott, Roche, Danaher, Siemens Healthineers & Thermo Fisher
Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher
Medical Equipment Cooling Market Forecasts Growth from $0.63B (2026) to $0.82B by 2031, Profiling Parker Hannifin, Daikin, Thermo Fisher & Boyd Corporation
Thermo Fisher Scientific (TMO) Launches Gibco CHO K1 Panel On A Fair Value Question
Thermo Fisher Scientific Inc. is a global life sciences company that provides analytical instruments, laboratory products, specialty diagnostics, and biopharma services. Its portfolio supports scientific research, clinical testing, drug discovery, and pharmaceutical manufacturing through a broad range of instruments, reagents, consumables, software, and services. The company serves customers across pharmaceutical and biotechnology firms, hospitals, clinical diagnostic laboratories, universities, research institutions, and government agencies. Thermo Fisher Scientific Inc. operates through several business segments that address research, analysis, diagnostics, and laboratory workflow needs, making it an important supplier to healthcare, industrial, and scientific markets worldwide. Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific Inc. is recognized for its role in enabling laboratory productivity and supporting the development, testing, and production of modern therapies and diagnostics.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest TMO und jede andere Aktie unbegrenzt.